Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 9Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 7Stomach Neoplasms 4Recurrence 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Lung Neoplasms 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Multiple Pulmonary Nodules 1Mid-low Rectal Cancer 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 20fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 15Cyclosporine 12Mycophenolic Acid 11Etoposide 9Busulfan 9Prednisone 8Vincristine 7Tacrolimus 7Filgrastim 7Carboplatin 7Bortezomib 7Antilymphocyte Serum 7Methotrexate 6Everolimus 6Doxorubicin 6Vorinostat 5Rituximab 5Gemcitabine 5Therapeutics 4Radiotherapy 4Panobinostat 4Paclitaxel 4Melphalan 4Lenalidomide 4Gene Expression Profiling 4Methylprednisolone 3MLN 8237 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoblastic Lymphadenopathy × tislelizumab × Clear all
NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

BeiGene

Phase 2 Completed
77 enrolled 20 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡